Arcutis (ARQT) Q3 2026 Earnings Call Transcript
Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise provide a fresh catalyst for short‑term price movement; longer‑term risk remains tied to clinical trial outcomes.
Market read
First‑time earnings release with upward guidance for a small‑cap biotech; actionable for traders monitoring biotech earnings beats.
What to watch
Higher SG&A spend and upcoming PDUFA dates could pressure cash flow later in 2027.
Background
Arcutis Biotherapeutics (NASDAQ:ARQT) is a specialty dermatology biotech focused on non‑steroidal topical treatments.
Ticker impact
Arcutis reported Q3 2026 results with $143.9M revenue and raised full-year guidance to $535‑$545M, a fresh earnings disclosure.
likely modest upside as market prices in higher guidance
Revenue up 45% YoY and guidance raised above prior range; investors may bid the stock higher.
Market effects
Positive for dermatology biotech sector as ZORYVE franchise shows strong demand.
US biotech market may see modest lift.
Limited to investors tracking small‑cap biotech earnings.
Counterpoint
Guidance raise may already be priced in; execution risk on upcoming trials could temper upside.
Key entities
- ExecutiveFrank Watanabe
President and CEO of Arcutis
- PartnerSimone Biles
World champion gymnast partnered with Arcutis for brand campaign
